These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15354286)

  • 1. The usefulness of PPD testing in inflammatory bowel disease patients before infliximab therapy.
    Uthman I; Sharara A
    Clin Gastroenterol Hepatol; 2004 Sep; 2(9):xxii. PubMed ID: 15354286
    [No Abstract]   [Full Text] [Related]  

  • 2. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.
    Mow WS; Abreu-Martin MT; Papadakis KA; Pitchon HE; Targan SR; Vasiliauskas EA
    Clin Gastroenterol Hepatol; 2004 Apr; 2(4):309-13. PubMed ID: 15067625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab.
    Cruz AT; Karam LB; Orth RC; Starke JR
    Pediatr Infect Dis J; 2014 Jul; 33(7):779-81. PubMed ID: 24469071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis].
    Obrador A; López San Román A; Muñoz P; Fortún J; Gassull MA;
    Gastroenterol Hepatol; 2003 Jan; 26(1):29-33. PubMed ID: 12525326
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 6. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY; Sanderson JD; Irving PM
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect].
    Zhou Y; Chen Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.
    Indriolo A; Fagiuoli S; Pasulo L; Fiorino G; Danese S; Ravelli P
    Aliment Pharmacol Ther; 2013 Apr; 37(8):840-2. PubMed ID: 23496317
    [No Abstract]   [Full Text] [Related]  

  • 12. IBD highlights from the 1999 American College of Gastroenterology meeting: infliximab and 6-MP.
    Wolf DC
    Inflamm Bowel Dis; 2000 Feb; 6(1):59-60. PubMed ID: 10701151
    [No Abstract]   [Full Text] [Related]  

  • 13. Multidrug resistant miliary tuberculosis during infliximab therapy despite tuberculosis screening.
    Gin A; Dolianitis C
    Australas J Dermatol; 2014 May; 55(2):140-1. PubMed ID: 23713793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-TNF agents in inflammatory bowel disease: indications and management].
    Cocq P; Yazdanpannah Y; Mesnard B; Colombel JF
    Gastroenterol Clin Biol; 2004 May; 28(5 Suppl):D61-9. PubMed ID: 15213665
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease.
    Rosh JR
    Curr Gastroenterol Rep; 2008 Jun; 10(3):302-7. PubMed ID: 18625142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Infliximab in inflammatory bowel diseases--conference summary and suggested guidelines].
    Dotan I; Chowers Y; Rachmilewitz D; Chermesh I; Lavy A; Israeli E; Karban A; Schwaber MJ; Odes S; Eliakim R
    Harefuah; 2006 Nov; 145(11):844-9, 860. PubMed ID: 17183961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miliary tuberculosis following infliximab therapy for Crohn disease: A case report and review of the literature.
    Stas P; D'Hoore A; Van Assche G; Geboes K; Steenkiste E; Penninckx F; Rutgeerts P; Vermeire S
    Acta Gastroenterol Belg; 2006; 69(2):217-20. PubMed ID: 16929619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.